

line 23, after "3'" insert --(SEQ ID NO:3) ←; and

line 28, after "3'" insert --(SEQ ID NO:4) ←.

IN THE CLAIMS:

Please cancel claim 7 without prejudice or disclaimer of any of the subject matter contained therein.

Please amend the claims as follows:

1. (Amended) ~~[/del] [An immunological] A test kit comprising~~

a) a first immobilized reagent having affinity to a specific macromolecule, and

b) [characterized in] a second and a third affinity reagent specific for different [determinantes] determinants of said macromolecule, and modified with crosslinkable oligonucleotides.

8<sup>2</sup>

2. (Amended) [An immunological] The test kit according to claim 1, [characterized in that] wherein the affinity reagents are antibodies, and [that] the macromolecule is a specific antigen.

sub  
C2

3. (Amended) [An immunological] The test kit according to claim 1, [characterized in that] wherein the affinity reagents

are lectins, receptors, single chain antibodies, cofactors [and]  
or nucleic acids.

4. (Amended) [An immunological] The test kit according to  
any one of the claims 1-3, **[characterized in that]** wherein the  
oligonucleotides are complementary to each other.

5. (Amended) [An immunological] The test kit according to  
claim 1, **[characterized in that it further comprises]** further  
comprising a ligase.

B<sup>2</sup>  
cont.  
6. An immunoassay for detection of a specific antigen,  
**[characterized in]** comprising:

a) contacting a sample suspected of containing said  
specific antigen with a first antibody linked to a solid  
support, said first antibody being specific for a first epitope  
on the antigen[,];

b) washing off excess reagents[,];

c) incubating with a solution of a second and a third  
antibody specific for a second and a third epitope of said  
antigen, and modified with crosslinkable oligonucleotides  
[enabling conjugation of] wherein

said second and third antibody become crosslinked when both are bound to the said, same antigen,

- B<sup>2</sup>  
cancel.
- d) washing off excess reagents,
  - e) amplifying said crosslinked oligonucleotides, and
  - f) detecting the amplified products.

B<sup>3</sup>  
sub  
C3

8. (Amended) An immunoassay according to claim 6 or 7, [characterized in that] further comprising adding an oligonucleotide complementary to the crosslinkable oligonucleotides [is added] before step d).

Please add the following new claims:

B<sup>4</sup>  
sub  
C4

--9. An immunoassay according to claim 6, wherein said crosslinkable oligonucleotides are complementary.--

--10. An immunoassay according to claim 8 or 9, further comprising adding a ligase before step d).--

REMARKS

Compliance with the Sequence Listing Requirements

The specification has been objected to for failing to comply with the Sequence Listing Requirements under 37 C.F.R.